BeaconLBS now offers Biocept's Target Selector™ testing for liquid biopsy as part of its laboratory management network in the United States SAN DIEGO , July 22, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians
SAN DIEGO , Aug. 5, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial
- Second quarter 2019 revenues increased 45% and commercial samples increased 26% over the second quarter of 2018 - Revenues for the first six-month of 2019 increased 36% and commercial samples increased 18% over the first six months of 2018 - Conference call begins at 4:30 p.m.
New patents further expand the Company's intellectual property estate for capturing and detecting rare cells of interest, including circulating tumor cells (CTCs), to aid in the management of patients with cancer Biocept now has 36 issued patents globally covering its novel liquid biopsy
Data highlight the ability of Biocept's patented and proprietary circulating tumor DNA assays to consistently detect actionable biomarkers from the blood of patients diagnosed with lung cancer at a mutant allele frequency as low as 0.01% SAN DIEGO , Aug. 22, 2019 /PRNewswire/ -- Biocept, Inc .
SAN DIEGO , Sept. 3, 2019 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that management will present at
Expands intellectual property to 37 issued patents globally for highly sensitive methods of detecting cancer biomarkers SAN DIEGO , Oct. 3, 2019 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically
Limit of detection of 0.02% or better enables accurate molecular profiling for treatment selection and dynamic monitoring of response to therapy using a simple blood sample SAN DIEGO , Oct. 7, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy
Data highlight strong analytical and clinical performance of Biocept's proprietary technologies, including circulating tumor DNA (ctDNA) assays, circulating tumor cell (CTC) capture, and molecular testing kits SAN DIEGO , Nov. 4, 2019 /PRNewswire/ -- Biocept, Inc .
SAN DIEGO , Nov. 6, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial
